Interviews - Psilocybin Alpha

New Resource: Psychedelics Drug Development Tracker

Interviews with the psychedelic sector’s leading Companies, organisations and individuals.

Nakul Raval, Researcher at the Neurobiology Research Unit, Copenhagen University Hospital

Nakul Raval, Researcher at the Neurobiology Research Unit, Copenhagen University Hospital

Post published:January 16, 2021
Post category:Interview

James Kuo, CEO and Co-founder of Tryp Therapeutics

James Kuo, CEO and Co-founder of Tryp Therapeutics

Post published:January 15, 2021
Post category:Interview

Jackie von Salm, Co-founder and CSO at Psilera Bioscience

Jackie von Salm, Co-founder and CSO at Psilera Bioscience

Post published:December 17, 2020
Post category:Interview

Lars Wilde, Co-founder of COMPASS Pathways

Lars Wilde, Co-founder of COMPASS Pathways

Post published:December 13, 2020
Post category:Interview

Andrew Chadeayne, Founder and CEO of CaaMTech

Andrew Chadeayne, Founder and CEO of CaaMTech

Post published:December 10, 2020
Post category:Interview

Nick Milne, Co-founder and CSO at Octarine Bio

Nick Milne, Co-founder and CSO at Octarine Bio

Post published:November 19, 2020
Post category:Interview

Oregon and DC Decriminalisation Initiative Successes: The Psychedelics Sector Reacts

Oregon and DC Decriminalisation Initiative Successes: The Psychedelics Sector Reacts

Post published:November 4, 2020
Post category:Interview News

Lynn Marie Morski, Psychedelic Medicine Association

Lynn Marie Morski, Psychedelic Medicine Association

Post published:September 25, 2020
Post category:Interview

Interview with Simeon Schnapper, Managing Partner of JLS

Interview with Simeon Schnapper, Managing Partner of JLS

Post published:September 24, 2020
Post category:Interview

Interview with Michael “Zappy” Zapolin, founder of Mind Army

Interview with Michael “Zappy” Zapolin, founder of Mind Army

Post published:September 17, 2020
Post category:Interview

End of content

No more pages to load

Psilocybin Alpha

The definitive resource for investors in the emergent psychedelic medicine sector. Cut through the shroom stock noise with exclusive news, interviews, data and private financing opportunities.

Quick Links

Newsletter

Industry insights and interviews delivered to your inbox. No spam, just valuable information.